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The induction of cytotoxic CD8+ T cell responses requires the presentation of antigenic
peptides by MHC class I molecules (MHC I). MHC I usually present peptides derived
from endogenous proteins. However, some subtypes of dendritic cells have developed
the ability to efﬁciently present peptides derived from exogenous antigens on MHC I via
a process called cross-presentation. Cross-presentation is intimately linked to the induc-
tion of anti-viral, -bacterial, and -tumor cytotoxic T cell (CTL) responses, as well as a wide
variety of CTL-mediated diseases and transplant rejections. The molecular and cellular
mechanisms underlying cross-presentation have been studied intensively since its orig-
inal description, yet understanding of this process is incomplete and on the forefront of
immunological research. Numerous pathways and models, some of them conﬂicting, have
been described so far. Here, we review the various pathways reported as involved in cross-
presentation, highlighting the complexity of this process. We also discuss in detail the
different intracellular steps required, from antigen capture and routing, to processing, and
ﬁnally peptide loading, emphasizing the need for a better understanding of the cell biology
of this phenomenon.
Keywords: antigen, cross-presentation, dendritic cell, MHC class I, phagosome, vaccination, cross-priming, gap
junctions
INTRODUCTION
Themammalian adaptive immune response is crucial in the clear-
ance of many infections. Classically, immune cells present exoge-
nous antigens on MHC Class II (MHC II) to “helper” CD4+ T
cells, and endogenous antigens viaMHCClass I (MHC I) to“cyto-
toxic” CD8+ T cells. In this review, we will focus on the CD8+ T
cells that are key in the elimination of infected or cancer cells.
CD8+ T cells are ﬁrst activated when their unique T cell receptor
(TCR) is triggered by fragments of microbial or tumor antigens in
association with MHC I. All nucleated cells express MHC I, how-
ever dendritic cells (DCs) also express a range of co-stimulatory
molecules, uptake receptors, and other key immune molecules to
speciﬁcally initiate a cytotoxic CD8+ T cells response.
In cases where DCs are not infected directly, but a cyto-
toxic T cell (CTL) response is required, DCs have the capacity
to sample antigens from their environment by a process called
cross-presentation, as it differs from the normal pathway of MHC
I antigen presentation where the antigens are merely cytoso-
lic or nuclear. For cross-presentation, exogenous antigens (e.g.,
from an infected cell) are taken up by DCs and rerouted to the
MHC I pathway for presentation to and activation of CD8+ T
cells.
The cell biology of cross-presentation is clearly different from
the classical MHC I antigen presentation. A myriad of studies
have interrogated various cell biological pathways including the
antigen uptake pathway, antigen translocation from endosome to
cytosol, ER–phagosome fusion, the proteasome, the endosomal
pH, the TAP transporter, and gap junctions (reviewed in Neefjes
et al., 2011; Segura and Villadangos, 2011). Based on these ﬁnd-
ings, various pathways and mechanisms have been proposed that
may all be correct or mutually exclusive. Here, we present a critical
evaluation of the various models and observations reported on
cross-presentation.
WHAT IS “TRUE” IN CROSS-PRESENTATION?
The classical pathway of MHC I antigen presentation is nowadays
understood in detail (Neefjes et al., 2011). Cytosolic and nuclear
antigens are degraded into peptide fragments by the proteasome,
further trimmed by peptidases, and transported from the cytosol
into the ER lumen by the peptide transporter TAP. Peptides are
then loaded on newly synthesizedMHC I and these complexes are
released from the ER and transported to the cell surface via the
Golgi.
As expected, the components of the classical MHC I anti-
gen presentation have been tested for their involvement in the
process of cross-presentation. In several studies, the proteasome
has been implicated in cross-presentation in experiments where
cells were treated with proteasome inhibitors for long periods of
time (Brossart and Bevan, 1997; Rodriguez et al., 1999). Here an
involvement of the proteasome in cross-presentation was implied
due to its role in generation of peptides. However, proteasome
inhibitors are known to alter the ubiquitin proﬁle in cells by accu-
mulating polyubiquitinated proteins and inducing alterations in
transcription due to histone deubiquitination (Dantuma et al.,
2006). Therefore, the inhibition of cross-presentation by pro-
teasome inhibitors might be the direct consequence of a defect
in peptide generation, or a subsequent event to transcriptome
alterations or to any other process involving ubiquitin such as
endosome formation.
Whether cross-presentation requires the peptide transporter
TAP was also tested. If involved, this would imply that antigenic
peptides originate from the cytosol, most likely after trimming by
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the proteasome. DCs isolated fromTAP-deﬁcientmice were found
unable to cross-present (Brossart and Bevan, 1997). However,
these observations have been contradicted by others (Dantuma
et al., 2006). Moreover, a recent model proposed by Merzougui
et al. implies a dissociation of TAP and proteasome dependence.
In particular, a role for TAP has been implicated in the recycling
of MHC I necessary for cross-presentation of particulate antigens
(Merzougui et al., 2011).
Finally, the involvement of newly synthesized MHC I in cross-
presentation was addressed using the chemical inhibitor Brefeldin
A which blocks ER–golgi transport (Brossart and Bevan, 1997).
Moreover, as it also affects the entire endosomal pathway, it is con-
ceivable that the inhibition of cross-presentation does not reﬂect
that peptide loading occurs onnewly synthesizedMHC I in the ER.
To conclude, some well accepted concepts concerning cross-
presentation can be contested, and it is important to reconsider
and take into account the different options.
CROSS-PRESENTATION, WHO IS ALLOCATED TO DO IT?
Cross-presentation is considered an exclusive feature to DCs.
Amongst the many subsets of DCs, the CD8α+ DCs in mouse and
their humanequivalent, theBDCA3+ DCs, themonocytes-derived
DCs (Mo-DCs), and the migratory CD103+ DCs are presumed to
be unique in their capacity to cross-present the antigen (in vitro
and in vivo; den Haan et al., 2000; del Rio et al., 2007; Hildner
et al., 2008; Bedoui et al., 2009; Bachem et al., 2010; Jongbloed
et al., 2010; Poulin et al., 2010). As our main focus in this review
is the cell biological aspect of cross-presentation, and as there has
been none performed with the CD103+ DCs,we will focus mainly
on the CD8α+ DCs and the Mo-DCs.
The obvious question iswhat distinguishes the cross-presenting
DC subsets from the others. Although the DC types have been
proﬁled by a series of techniques including microarray and mass
spectrometry, a clear “cross-presentation signature” has not been
deﬁned (Robbins et al., 2008; Luber et al., 2010; Segura et al., 2010).
One option is that all cells (including non-immune cells) are able
to cross-present but the cross-presenting DCs are just remarkable
because they display the perfect arsenal of the required charac-
teristics for this process, from the surface expression of speciﬁc
uptake receptors, a low endosomal protease activity, an extremely
high expression of MHC I and ﬁnally a series of co-stimulatory
molecules to allow cross-priming. These DCs may therefore be
better equipped, without being unique. This would explain why
cross-presentation has also been observed, but to a lesser extent, in
other immune cells like CD8α− DCs (denHaan and Bevan, 2002),
Langerhans cells (Oh et al., 2011), B cells (de Wit et al., 2010),
macrophages (Asano et al., 2011), as well as in non-immune cells
(Gromme et al., 1999;Neijssen et al., 2005; Pang et al., 2009). Alter-
natively, the cross-presenting DCsmay have a cell biological secret
that is yet to be revealed.
RECEPTOR-MEDIATED ANTIGEN UPTAKE AND ROUTING TO
THE MHC I PATHWAY
One issue that is not contested is that exogenous antigens have tobe
captured by DCs for cross-presentation (Figure 1). Antigens can
be taken up by ﬂuid phase or by receptor-mediated endocytosis.
A number of endocytosis/phagocytosis receptors have long been
thought to be critical for antigen uptake as they concentrate anti-
gens in the endocytic pathway. However, many of them have a
more important function in rerouting and targeting the antigen
to deﬁned endosomal compartments: efﬁcient uptake in combi-
nation with cargo delivery to the appropriate compartments is
a decisive event for antigen cross-presentation (Burgdorf et al.,
2007; Caminschi et al., 2008; Sancho et al., 2009; Tacken et al.,
2011).
A series of receptors have been implicated including Fcγ recep-
tors (den Haan and Bevan, 2002; Schuurhuis et al., 2002) and
lectin receptors such as the mannose receptor that mediates the
uptake of soluble but not cell-associated antigens (Burgdorf et al.,
2006), Dectin-1 that is involved in uptake and cross-presentation
of cellular antigen (Weck et al., 2008), Clec9A that mediates the
capture and cross-presentation of antigens derived from necrotic
cells (Caminschi et al., 2008; Sancho et al., 2009), and others.
Collectively, these studies illustrate that different antigens
can use multiple uptake mechanisms and pathways leading to
cross-presentation of antigenic peptides on MHC I.
ARE ALL ENDOSOMES EQUAL FOR CROSS-PRESENTATION?
Aswritten in classical textbooks, captured antigens enter the endo-
cytic pathway.Antigens ﬁrst enter early endosomes, then late endo-
somes, and ﬁnally lysosomes. In the case of cell-associated antigens
or bacteria, the endosomes are enlarged and called phagosomes.
Each of these compartments has speciﬁc markers and pH. Early
endosomes are positive for Rab5 and are mildly acidic without
many proteases while late endosomes and lysosomes are positive
for Rab7 and more acidic (around pH 5.0) with a substantial
proteolytic activity. However, this concept of a simple endoso-
mal pathway, where material moves from early to late endosomes
then to lysosomes as their inescapable fate, has been challenged for
many years especially through the description of lysosome-related
organelles such as cytotoxic granules, melanosomes, and MHC
II loading compartments (MIIC). The endosomal pathway can
therefore undergo specialization, and this may be applied in anti-
gen cross-presentation (Lakadamyali et al., 2006; Burgdorf et al.,
2007; Saveanu et al., 2009; Tacken et al., 2011).
In this regard, Lakadamyali et al. showed that internalized
proteins can be sorted into two different categories of early endo-
somes, “dynamic” or “static.” The dynamic population matured
rapidly toward late endosomes and subsequently fused with lyso-
somes yielding material for MHC II antigen presentation. The
more “static” population displayed a slower maturation rate
(Lakadamyali et al., 2006), that would favor cross-presentation,
as it displayed a low proteolytic activity, which is believed to pro-
tect antigens from excessive destruction (Savina et al., 2006; Jancic
et al., 2007). Interestingly, the mannose receptor (Burgdorf et al.,
2007) and DC-SIGN (Tacken et al., 2011) are surface receptors
that target antigens to these low maturating compartments and
that mediate cross-presentation.
But what speciﬁes these endosomes involved in cross-
presentation? They are marked by the GTPase Rab14, and contain
MHC I and the trimming peptidase IRAP (Saveanu et al., 2009).
Of note, Salmonella-containing phagosomes are also marked by
Rab14, a GTPase that controls phagosomal fusion with lysosomes
(Kuijl et al., 2007).
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FIGURE 1 | Multiple ways for MHC I cross-presentation. After uptake,
antigens can follow different routes and be targeted to (1) slow maturating
endosomes (or phagosome) displaying low proteolytic activity. Then, antigens
can escape to the cytosol (via HSP90) and are degraded by the proteasome
into peptides that are translocated to the ER or back to the endocytic
compartment for loading; (2) Fast maturating endosomes, addressing the
antigens to low pH- and high proteolytic- compartments suited for MHC II
antigen presentation; (3) Recycling endosomes, where loading occurs on
recycling MHC I molecules. Gap junctions mediate transfer of small peptides
between neighboring cells. LC, loading complex.
Some studies have provided functional evidence for the pres-
ence of endosomal compartments in DCs dedicated for long-
term storage of antigen, therefore providing material for cross-
presentation by MHC I over long periods of time after uptake
(Faure et al., 2009; vanMontfoort et al., 2009).Whether the “static
Rab14 endosome” corresponds to the long-term antigen storage
organelle is, however, unclear.
ANTIGEN PROCESSING FOR CROSS-PRESENTATION
AsMHC I classically presents fragments of antigens in the form of
8–10 amino acid long peptides, antigens have to be processed for
cross-presentation (Neefjes et al., 2011). A low proteolytic endo-
somal activity, characteristic of the CD8+ DCs, is believed to be
decisive to avoid excessive antigen destruction and allow its pro-
cessing for cross-presentation (Delamarre et al., 2005; Savina et al.,
2006; Jancic et al., 2007). Endocytosed antigens can be processed
for cross-presentation by different pathways most likely display-
ing distinct proteolytic speciﬁcities: (1) by endosomal proteases
such as cathepsin S and D (Fonteneau et al., 2003; Shen et al.,
2004) and (2) by the cytosolic proteasomal machinery used in the
classical MHC I antigen presentation pathway (Fonteneau et al.,
2003; Shen et al., 2004; Neefjes et al., 2011) which implies that
exogenous antigens ﬁnd a way to enter the cytosol for degradation
by the proteasome. Various reports present different solutions to
this topological problem.
Antigen translocation from the endosome to the cytosol has
been proposed to be speciﬁc to internalized antigen and depen-
dent on the size (Rodriguez et al., 1999). As most proteins do
not spontaneously pass lipid bilayers, this would require a ded-
icated – unknown – transporter. Most models imply the ER
retrotranslocation machinery (ERAD) involved in the transloca-
tion of misfolded ER proteins into the cytosol for degradation by
the proteasome (Haug et al., 2003; Taylor et al., 2010; Imai et al.,
2011; Oura et al., 2011). Two recent studies demonstrate a role for
the chaperone HSP90 in this process (Imai et al., 2011; Oura et al.,
2011). An independent study of the group of Cresswell showed
that some antigens might be transported from endosomes back to
the ER and delivered to the cytosol by the ERAD machinery fol-
lowed by degradation by the proteasome (Ackerman et al., 2005).
This mechanism is used by some toxins to enter the cytosol, but
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is poorly – if at all – used by most proteins (Neefjes et al., 1988).
It is therefore unlikely to be the major route. A role for the man-
nose receptor in antigen translocation to the cytosol has also been
suggested (Burgdorf et al., 2008; Zehner et al., 2011). The underly-
ing mechanisms remain unclear but it is unlikely that the receptor
itself performs the translocation step.
An alternativemodel implicating a fusion of the ERwith phago-
somes has been suggested by several groups (Gagnon et al., 2002;
Guermonprez et al., 2003; Houde et al., 2003). This process may
involve a Sec22b-dependent fusion of ER–golgi intermediate com-
partments with the phagosome (Cebrian et al., 2011), an event that
would allow a recruitment of the ERAD machinery to the phago-
some, and therefore antigen translocation to the cytosol where
proteasomal degradationﬁnally occurs. Peptides can then either be
transported by TAP into the newly formed ER–phagosome hybrid
organelle or to the ER for loading (Gagnon et al., 2002; Guermon-
prez et al., 2003;Houde et al., 2003). Thesemodels are fairly unique
in cell biology andmake assumptions that (1) the energy for ERAD
is available in the ER–phagosome hybrid organelle, and (2) the
chaperones involved in directing antigens to ERAD recognize and
consider the antigens sufﬁcientlymisfolded for degradation. These
considerations complicate the involvement of the ERAD system in
cross-presentation and reinforces the fact that the antigen export
machinery and especially the actual retrotranslocon pore remains
to be deﬁned.
PEPTIDE LOADING
Although there may be various pathways for cross-presentation
and different locations for antigen processing, peptides and MHC
I ﬁnally have tomeet in the same compartment or organelle. These
meeting point options suggested so far are:
– In the ER. This pathway is the most evident from the MHC I
point of view as it represents the classical pathway for efﬁcient
peptide loading in the presence of the completeMHC Imachin-
ery. This pathway has been extensively studied and is nowadays
understood in detail (Neefjes et al., 2011). The major issue is
how exogenous antigens enter this pathway in an efﬁcient man-
ner to compete for loading with the myriad of peptides that are
in the ER.
– In endosomes. This pathway would be simpler as it does not
require (unknown) mechanisms for delivering antigens to the
cytosol. Antigens would simply be degraded by endosomal pro-
teases and peptides loaded on recycling MHC I. Peptide release
and exchange can occur efﬁciently under mild acidic condi-
tions, without the support of chaperones (Gromme et al., 1999;
Burgdorf et al., 2006; Di Pucchio et al., 2008; Zou et al., 2009;
Win et al., 2011).
ALTERNATIVE MECHANISMS FOR CROSS-PRESENTATION
Cross-presentation may also result from the transfer of MHC
I-peptide complexes from infected cells or tumor to DCs via exo-
somes or trogocytosis (Wolfers et al., 2001; Herrera et al., 2004;
Wakim and Bevan, 2011). Whether these processes are relevant
in vivo is unclear.
An alternative that would solve the topological problem of
exogenous antigendelivery to the cytosol of DCs is peptide transfer
via gap junctions (Neijssen et al., 2005). Gap junctions are small
channels directly connecting the cytosol of two adjacent cells (Nei-
jssen et al., 2007). The proteins constituting the gap junctions are
called connexins and these are upregulated onmonocytes andDCs
upon exposure to danger signals (Pang andNeefjes, 2010; Saccheri
et al., 2010). Gap junctions are able tomediate the transfer of small
peptides from apoptotic and tumor cells to DCs (Pang et al., 2009;
Saccheri et al., 2010). The transferred peptides have been shown
to be efﬁciently presented by MHC I at the cell surface to trigger
activation of speciﬁc CD8+ T cells (Neijssen et al., 2005; Pang and
Neefjes, 2010; Saccheri et al., 2010).
THE FINAL STEP: CELL SURFACE DELIVERY FOR
CROSS-PRESENTATION
Ultimately, MHC I molecules have to present antigenic informa-
tion at the cell surface. Depending on the site of peptide loading,
the route of the MHC I-peptides complexes to the cell surface
differs. If peptide loading occurs in the ER, complexes simply fol-
low the standard secretory pathway (Neefjes et al., 2011). If MHC
I molecules acquire antigenic peptides in endosomal compart-
ments, they may use the pathway also used by MHC II molecules
after peptide loading in the MIIC (Gromme et al., 1999).
CONCLUDING REMARKS AND BEYOND
The last few decades have uncovered profound insights into the
biology of antigen presentation, but many components still have
to be deﬁned to unequivocally understand the complex cross-
presentation logistics fromantigenuptake and routing,processing,
and peptide loading. The many conﬂicting opinions in the ﬁeld
might be partially explained by the fact that the process has dif-
ferent requirements depending on the cell type (e.g., CD8α+ vs
CD8α− DC orMo-DCs), on the antigen form (soluble, antibody-,
or cell- associated), and source (necrotic, apoptotic, infected, or
tumor cell), and on the uptake route (gap junctions, receptor-
mediated endocytosis). Also, we cannot exclude the option that
multiple pathways may be active in the cross-presentation of a
speciﬁc antigen. Moreover, a study on the cell biology of cross-
presentation usually focuses on one step of the process, with-
out relating it to the upstream and downstream events. For the
above reasons, drawing a general consensual scheme of cross-
presentation based on independent studies is akin to putting
together a picture puzzle using a collection of pieces originating
from different sources.
Another consideration is the difference in kinetics between the
differentmechanisms. The endosomal cross-presentation pathway
may be faster that the cytosolic one, allowing rapid expression of
signiﬁcant levels of MHC I with cross-presented peptides at the
cell surface (Burgdorf et al., 2008; Di Pucchio et al., 2008). More-
over, the pathways engaged for cross-presentation appear to be cell
type dependent (Segura et al., 2009).While inﬂammatoryMo-DCs
may be relying mainly on the fast endosomal pathway, the ability
of “steady state” CD8α+ DCs to cross-present seems to depend
more on the cytosolic pathway. All these variations should have
major implications when the cell biology of cross-presentation is
translated into the design of new therapies aiming to target cross-
presentation byDCs to stimulate speciﬁcCTL to control infections
and cancer.
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